Search Results - "Van Eygen, V." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

by Sulkowski, M. S., Feld, J. J., Lawitz, E., Felizarta, F., Corregidor, A. M., Khalid, O., Ghalib, R., Smith, W. B., Van Eygen, V., Luo, D., Vijgen, L., Gamil, M., Kakuda, T. N., Ouwerkerk‐Mahadevan, S., Van Remoortere, P., Beumont, M.
Published in Journal of viral hepatitis (01.06.2018)

Get full text

Journal Article

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

by Lawitz, E., Poordad, F., Gutierrez, J. A., Kakuda, T. N., Picchio, G., Beets, G., Vandevoorde, A., Van Remoortere, P., Jacquemyn, B., Luo, D., Ouwerkerk‐Mahadevan, S., Vijgen, L., Van Eygen, V., Beumont, M.
Published in Journal of viral hepatitis (01.04.2017)

Get full text

Journal Article

Consistent Simeprevir Resistance Profile in Hepatitis C Virus Genotype 1-Infected Patients Failing Simeprevir Interferon-Free Compared with Interferon-Containing Regimens

by Fevery, B, Vijgen, L, Van Eygen, V, Jessner, W, Corbett, C, Schlag, M, Lenz, O, De Meyer, S
Published in Journal of hepatology (2016)

Get full text

Journal Article

Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and -Experienced Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and -Experienced Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

by Sarrazin, C, Van Eygen, V, Vijgen, L, Gamil, M, Beumont, M, Lawitz, E, De Meyer, S
Published in Journal of hepatology (2016)

Get full text

Journal Article

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen

by Bourgeois, S, Horsmans, Y, Nevens, F, van Vlierberghe, H, Moreno, C, Beumont, M, van de Logt, J, Vijgen, L, van Eygen, V, Luo, D, Hillewaert, V, Van Remoortere, P, Ouwerkerk-Mahadevan, S
Published in Journal of hepatology (2016)

Get full text

Journal Article

P220 DEEP SEQUENCING ANALYSES OF MINORITY BASELINE POLYMORPHISMS AND PERSISTENCE OF EMERGING MUTATIONS IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH SIMEPREVIR

P220 DEEP SEQUENCING ANALYSES OF MINORITY BASELINE POLYMORPHISMS AND PERSISTENCE OF EMERGING MUTATIONS IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH SIMEPREVIR

by Fevery, B, Thys, K, Van Eygen, V, Verbinnen, T, Van Rossem, E, Picchio, G, De Meyer, S, Lenz, O
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

LP07 : Simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study

LP07 : Simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study

by Lawitz, E, Poordad, F, Gutierrez, J, Kakuda, T, Picchio, G, Rosa, G. De La, Beets, G, Vandevoorde, A, Van Remoortere, P, Jacquemyn, B, Quinn, G, Luo, D, Ouwerkerk-Mahadevan, S, Vijgen, L, Van Eygen, V, Beumont, M
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

P1194 EVALUATION OF OPTIMAL HCV RNA CUT-OFFS WITH TWO MAJOR REAL-TIME PCR-BASED ASSAYS FOR RESPONSE-GUIDED TRIPLE THERAPY WITH TELAPREVIR

P1194 EVALUATION OF OPTIMAL HCV RNA CUT-OFFS WITH TWO MAJOR REAL-TIME PCR-BASED ASSAYS FOR RESPONSE-GUIDED TRIPLE THERAPY WITH TELAPREVIR

by Sarrazin, C, Dierynck, I, Cloherty, G, Ghys, A, Janssen, K, Van Eygen, V, Luo, D, Witek, J, Buti, M, Picchio, G, De Meyer, S
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

P1199 RE-TREATMENT WITH TELAPREVIR-BASED TRIPLE THERAPY AFTER TELAPREVIR EXPOSURE IN PHASE 1 STUDIES: DEEP SEQUENCE ANALYSIS FOR PERSISTENCE OF RESISTANT VARIANTS

P1199 RE-TREATMENT WITH TELAPREVIR-BASED TRIPLE THERAPY AFTER TELAPREVIR EXPOSURE IN PHASE 1 STUDIES: DEEP SEQUENCE ANALYSIS FOR PERSISTENCE OF RESISTANT VARIANTS

by Susser, S, Flinders, M, Reesink, H.W, Zeuzem, S, Lawyer, G, Ghys, A, Van Eygen, V, Witek, J, De Meyer, S, Sarrazin, C
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

THU-215 - Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and -Experienced Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

THU-215 - Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and -Experienced Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

by Sarrazin, C., Van Eygen, V., Vijgen, L., Gamil, M., Beumont, M., Lawitz, E., De Meyer, S.
Published in Journal of hepatology (2016)

Get full text

Journal Article

THU-214 - Consistent Simeprevir Resistance Profile in Hepatitis C Virus Genotype 1-Infected Patients Failing Simeprevir Interferon-Free Compared with Interferon-Containing Regimens

by Fevery, B., Vijgen, L., Van Eygen, V., Jessner, W., Corbett, C., Schlag, M., Lenz, O., De Meyer, S.
Published in Journal of hepatology (2016)

Get full text

Journal Article

Observational cohort study of rilpivirine (RPV) utilization in Europe

Observational cohort study of rilpivirine (RPV) utilization in Europe

by Cozzi-Lepri, Alessandro, Peters, Lars, Pelchen-Matthews, Annegret, Neesgaard, Bastian, De Wit, Stephane, Johansen, Isik Somuncu, Edwards, Simon, Stephan, Christoph, Adamis, Georgios, Staub, Therese, Zagalo, Alexandra, Domingo, Pere, Elbirt, Daniel, Kusejko, Katharina, Brännström, Johanna, Paduta, Dzmitry, Trofimova, Tatyana, Szlavik, Janos, Zilmer, Kai, Losso, Marcello, Van Eygen, Veerle, Pai, Helen, Lundgren, Jens, Mocroft, Amanda
Published in AIDS research and therapy (06.08.2022)

Get full text

Journal Article

SAT-264 - Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen

SAT-264 - Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen

by Bourgeois, S., Horsmans, Y., Nevens, F., van Vlierberghe, H., Moreno, C., Beumont, M., van de Logt, J., Vijgen, L., van Eygen, V., Luo, D., Hillewaert, V., Van Remoortere, P., Ouwerkerk-Mahadevan, S.
Published in Journal of hepatology (2016)

Get full text

Journal Article

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

by VAN BAELEN, Kurt, VAN EYGEN, Veerle, RONDELEZ, Evelien, STUYVER, Lieven J
Published in AIDS (London) (12.09.2008)

Get full text

Journal Article

Re-treatment of hepatitis C virus genotype 1 infected patients with telaprevir-based triple therapy after telaprevir exposure in Phase 1 studies: deep sequencing analysis for persistence of resistant variants

Re-treatment of hepatitis C virus genotype 1 infected patients with telaprevir-based triple therapy after telaprevir exposure in Phase 1 studies: deep sequencing analysis for persistence of resistant variants

by Susser, S, Flinders, M, Reesink, H W, Zeuzem, S, Lawyer, G, Ghys, A, Van Eygen, V, Witek, J, De Meyer, S, Sarrazin, C
Published in Antiviral therapy (01.01.2014)

Get full text

Journal Article

In vitro selection experiments with rilpivirine and/or emtricitabine using clinical isolates, with E138K and/or M184I, obtained from patients with virological failure

In vitro selection experiments with rilpivirine and/or emtricitabine using clinical isolates, with E138K and/or M184I, obtained from patients with virological failure

by Vingerhoets, J, Rimsky, L T, Van Ginderen, M, Strijbos, R, Van Eygen, V, Dams, G, De Meyer, S
Published in Antiviral therapy (01.01.2013)

Get full text

Journal Article

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment

by VANDEKEREKHOVE, Linos, VERHOFSTEDE, Chris, PLUM, Jean, VAIRA, Dolores, VAN BAELEN, Kurt, VANDENBROUCKE, Ina, VAN EYGEN, Veerle, VAN MARCK, Herwig, VOGETAERS, Dirk, GERETTI, Anna Maria, STUYVER, Lieven J, DEMECHELEER, Els, DE WIT, Stephane, FLORENCE, Eric, FRANSEN, Katrien, MOUTSCHEN, Michel, MOSTMANS, Wendy, KABEYA, Kabamba, MACKIE, Nicola
Published in Journal of antimicrobial chemotherapy (01.02.2011)

Get full text

Journal Article Web Resource

Simeprevir in HCV genotype-1-infected patients: deep sequencing analyses of the PILLAR and ASPIRE Phase IIb trials

Simeprevir in HCV genotype-1-infected patients: deep sequencing analyses of the PILLAR and ASPIRE Phase IIb trials

by Lenz, O, Fevery, B, Thys, K, Van Eygen, V, Aerssens, J, Reumers, J, Peeters, M, Verbinnen, T, Beumont-Mauviel, M, Picchio, G
Published in Antiviral therapy (01.01.2013)

Get full text

Journal Article

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

by Sulkowski, M S, Feld, J J, Lawitz, E, Felizarta, F, Corregidor, A M, Khalid, O, Ghalib, R, Smith, W B, Van Eygen, V, Luo, D, Vijgen, L, Gamil, M, Kakuda, T N, Ouwerkerk-Mahadevan, S, Van Remoortere, P, Beumont, M
Published in Journal of viral hepatitis (23.12.2017)

Get full text

Journal Article

HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays

HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays

by Van Baelen, Kurt, Vandenbroucke, Ina, Rondelez, Evelien, Van Eygen, Veerle, Vermeiren, Hans, Stuyver, Lieven J.
Published in Journal of virological methods (01.12.2007)

Get full text

Journal Article